DexCom (NASDAQ:DXCM) Downgraded by BidaskClub to Hold

BidaskClub lowered shares of DexCom (NASDAQ:DXCM) from a buy rating to a hold rating in a research report report published on Wednesday, June 26th, BidAskClub reports.

Other analysts have also issued research reports about the company. BMO Capital Markets raised TMAC Resources from a market perform rating to an outperform rating in a report on Thursday, May 2nd. Zacks Investment Research lowered GALP ENERGIA SG/ADR from a hold rating to a sell rating in a research report on Monday, May 6th. UBS Group lifted their price target on Spotify Technology from $180.00 to $182.00 and gave the stock a buy rating in a research report on Tuesday, April 30th. Northland Securities reaffirmed a hold rating and issued a $125.00 price target on shares of DexCom in a research report on Thursday, June 6th. Finally, Piper Jaffray Companies lifted their price target on DexCom to $173.00 and gave the stock an overweight rating in a research report on Wednesday, May 1st. Five analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the stock. The stock presently has a consensus rating of Buy and a consensus price target of $150.65.

DexCom stock traded up $5.82 during trading hours on Wednesday, hitting $153.39. 908,951 shares of the stock were exchanged, compared to its average volume of 1,268,816. DexCom has a 12 month low of $92.33 and a 12 month high of $157.50. The stock has a 50-day moving average of $141.68. The stock has a market capitalization of $13.40 billion, a PE ratio of 511.30 and a beta of 0.82. The company has a quick ratio of 6.75, a current ratio of 7.18 and a debt-to-equity ratio of 1.57.

DexCom (NASDAQ:DXCM) last issued its earnings results on Wednesday, May 1st. The medical device company reported ($0.05) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.17) by $0.12. DexCom had a negative net margin of 11.51% and a positive return on equity of 8.45%. The firm had revenue of $280.50 million during the quarter, compared to the consensus estimate of $246.10 million. During the same quarter in the prior year, the firm earned ($0.30) earnings per share. The business’s quarterly revenue was up 52.1% on a year-over-year basis. As a group, sell-side analysts expect that DexCom will post 0.81 EPS for the current year.

In other DexCom news, EVP Steven Robert Pacelli sold 3,596 shares of DexCom stock in a transaction that occurred on Tuesday, April 23rd. The stock was sold at an average price of $116.61, for a total value of $419,329.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Steven R. Altman sold 2,500 shares of DexCom stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $151.62, for a total value of $379,050.00. Following the completion of the transaction, the director now owns 2,676 shares of the company’s stock, valued at $405,735.12. The disclosure for this sale can be found here. In the last quarter, insiders have sold 64,645 shares of company stock worth $8,317,066. 1.80% of the stock is owned by insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of DXCM. Gateway Investment Advisers LLC lifted its holdings in shares of DexCom by 18.3% in the second quarter. Gateway Investment Advisers LLC now owns 24,497 shares of the medical device company’s stock worth $3,671,000 after buying an additional 3,791 shares in the last quarter. Juncture Wealth Strategies LLC purchased a new stake in DexCom during the 2nd quarter valued at approximately $587,000. Gradient Investments LLC purchased a new stake in DexCom during the 2nd quarter valued at approximately $25,000. IFM Investors Pty Ltd raised its stake in shares of DexCom by 23.7% during the 2nd quarter. IFM Investors Pty Ltd now owns 6,306 shares of the medical device company’s stock worth $945,000 after buying an additional 1,210 shares in the last quarter. Finally, OLD National Bancorp IN raised its stake in shares of DexCom by 1.1% during the 2nd quarter. OLD National Bancorp IN now owns 9,838 shares of the medical device company’s stock worth $1,474,000 after buying an additional 108 shares in the last quarter. 96.40% of the stock is currently owned by institutional investors.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.

Recommended Story: What is meant by holder of record?

Analyst Recommendations for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.